131 related articles for article (PubMed ID: 37918680)
21. Antrodia cinnamomea and its compound dehydroeburicoic acid attenuate nonalcoholic fatty liver disease by upregulating ALDH2 activity.
Cao YN; Yue SS; Wang AY; Xu L; Hu YT; Qiao X; Wu TY; Ye M; Wu YC; Qi R
J Ethnopharmacol; 2022 Jun; 292():115146. PubMed ID: 35304272
[TBL] [Abstract][Full Text] [Related]
22. FXR Inhibits Endoplasmic Reticulum Stress-Induced NLRP3 Inflammasome in Hepatocytes and Ameliorates Liver Injury.
Han CY; Rho HS; Kim A; Kim TH; Jang K; Jun DW; Kim JW; Kim B; Kim SG
Cell Rep; 2018 Sep; 24(11):2985-2999. PubMed ID: 30208322
[TBL] [Abstract][Full Text] [Related]
23. Asperuloside alleviates lipid accumulation and inflammation in HFD-induced NAFLD via AMPK signaling pathway and NLRP3 inflammasome.
Shen Q; Chen Y; Shi J; Pei C; Chen S; Huang S; Li W; Shi X; Liang J; Hou S
Eur J Pharmacol; 2023 Mar; 942():175504. PubMed ID: 36641101
[TBL] [Abstract][Full Text] [Related]
24. Yangonin protects against non-alcoholic fatty liver disease through farnesoid X receptor.
Dong R; Yang X; Wang C; Liu K; Liu Z; Ma X; Sun H; Huo X; Fu T; Meng Q
Phytomedicine; 2019 Feb; 53():134-142. PubMed ID: 30668392
[TBL] [Abstract][Full Text] [Related]
25. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
Serviddio G; Bellanti F; Vendemiale G
Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease development.
He K; Zhu X; Liu Y; Miao C; Wang T; Li P; Zhao L; Chen Y; Gong J; Cai C; Li J; Li S; Ruan XZ; Gong J
Oncotarget; 2017 Jun; 8(23):37657-37672. PubMed ID: 28499273
[TBL] [Abstract][Full Text] [Related]
27. High fat diet feeding results in gender specific steatohepatitis and inflammasome activation.
Ganz M; Csak T; Szabo G
World J Gastroenterol; 2014 Jul; 20(26):8525-34. PubMed ID: 25024607
[TBL] [Abstract][Full Text] [Related]
28. Hepatocellular cystathionine γ lyase/hydrogen sulfide attenuates nonalcoholic fatty liver disease by activating farnesoid X receptor.
Xu W; Cui C; Cui C; Chen Z; Zhang H; Cui Q; Xu G; Fan J; Han Y; Tang L; Targher G; Byrne CD; Zheng MH; Yang L; Cai J; Geng B
Hepatology; 2022 Dec; 76(6):1794-1810. PubMed ID: 35586979
[TBL] [Abstract][Full Text] [Related]
29. GCN2 deficiency protects against high fat diet induced hepatic steatosis and insulin resistance in mice.
Liu S; Yuan J; Yue W; Bi Y; Shen X; Gao J; Xu X; Lu Z
Biochim Biophys Acta Mol Basis Dis; 2018 Oct; 1864(10):3257-3267. PubMed ID: 30006154
[TBL] [Abstract][Full Text] [Related]
30. Bisphenol A induced hepatic steatosis by disturbing bile acid metabolism and FXR/TGR5 signaling pathways via remodeling the gut microbiota in CD-1 mice.
Hong T; Zou J; He Y; Zhang H; Liu H; Mai H; Yang J; Cao Z; Chen X; Yao J; Feng D
Sci Total Environ; 2023 Sep; 889():164307. PubMed ID: 37211107
[TBL] [Abstract][Full Text] [Related]
31. Obeticholic acid inhibits hepatic fatty acid uptake independent of FXR in mouse.
Lin C; Yu B; Liu X; Chen L; Zhang Z; Ye W; Zhong H; Bai W; Yang Y; Nie B
Biomed Pharmacother; 2022 Jun; 150():112984. PubMed ID: 35447541
[TBL] [Abstract][Full Text] [Related]
32. Hepatoprotective effect of Typhaneoside on non-alcoholic fatty liver disease via farnesoid X receptor in vivo and in vitro.
Zheng Y; Zhao J; Miao D; Xu T; Wang L; Liu C; Gao Y; Yu L; Shen C
Biomed Pharmacother; 2023 Aug; 164():114957. PubMed ID: 37295248
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-122 Inhibits Lipid Droplet Formation and Hepatic Triglyceride Accumulation via Yin Yang 1.
Wu GY; Rui C; Chen JQ; Sho E; Zhan SS; Yuan XW; Ding YT
Cell Physiol Biochem; 2017; 44(4):1651-1664. PubMed ID: 29216638
[TBL] [Abstract][Full Text] [Related]
34. Farnesoid X receptor activation induces the degradation of hepatotoxic 1-deoxysphingolipids in non-alcoholic fatty liver disease.
Gai Z; Gui T; Alecu I; Lone MA; Hornemann T; Chen Q; Visentin M; Hiller C; Hausler S; Kullak-Ublick GA
Liver Int; 2020 Apr; 40(4):844-859. PubMed ID: 31883408
[TBL] [Abstract][Full Text] [Related]
35. The ameliorating effect of withaferin A on high-fat diet-induced non-alcoholic fatty liver disease by acting as an LXR/FXR dual receptor activator.
Shiragannavar VD; Sannappa Gowda NG; Puttahanumantharayappa LD; Karunakara SH; Bhat S; Prasad SK; Kumar DP; Santhekadur PK
Front Pharmacol; 2023; 14():1135952. PubMed ID: 36909161
[No Abstract] [Full Text] [Related]
36. Population-based meta-analysis and gene-set enrichment identifies FXR/RXR pathway as common to fatty liver disease and serum lipids.
Handelman SK; Puentes YM; Kuppa A; Chen Y; Du X; Feitosa MF; Palmer ND; Speliotes EK
Hepatol Commun; 2022 Nov; 6(11):3120-3131. PubMed ID: 36098472
[TBL] [Abstract][Full Text] [Related]
37. Zinc-α2-glycoprotein 1 attenuates non-alcoholic fatty liver disease by negatively regulating tumour necrosis factor-α.
Liu T; Luo X; Li ZH; Wu JC; Luo SZ; Xu MY
World J Gastroenterol; 2019 Sep; 25(36):5451-5468. PubMed ID: 31576092
[TBL] [Abstract][Full Text] [Related]
38. Hepatic Clstn3 Ameliorates Lipid Metabolism Disorders in High Fat Diet-Induced NAFLD through Activation of FXR.
Guo J; Huang S; Yi Q; Liu N; Cui T; Duan S; Chen J; Li J; Li J; Wang L; Gao Y; Nie G
ACS Omega; 2023 Jul; 8(29):26158-26169. PubMed ID: 37521618
[TBL] [Abstract][Full Text] [Related]
39. Restraint stress promotes nonalcoholic steatohepatitis by regulating the farnesoid X receptor/NLRP3 signaling pathway.
Yang F; Lv XT; Lin XL; Wang RH; Wang SM; Wang GE
Acta Biochim Biophys Sin (Shanghai); 2023 Dec; 55(12):1961-1971. PubMed ID: 37997375
[TBL] [Abstract][Full Text] [Related]
40. Both bone marrow-derived and non-bone marrow-derived cells contribute to AIM2 and NLRP3 inflammasome activation in a MyD88-dependent manner in dietary steatohepatitis.
Csak T; Pillai A; Ganz M; Lippai D; Petrasek J; Park JK; Kodys K; Dolganiuc A; Kurt-Jones EA; Szabo G
Liver Int; 2014 Oct; 34(9):1402-13. PubMed ID: 24650018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
